SHANGHAI, March 17, 2024 /PRNewswire/ — Everest Medicines (HKEX: 1952.HK, “Everest,” or the “Company”), a biopharmaceutical company focused on the…
Browsing: Everest Medicines
— Macau is on course to become the first of Everest’s Asian territories to get etrasimod approval — Can provide…
SHANGHAI, China and SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 /PRNewswire/ — Everest Medicines (HKEX 1952.HK) and Kezar Life Sciences,…
-Everest will continue to develop self-discovered products utilizing the mRNA platform- SHANGHAI, Feb. 18, 2024 /PRNewswire/ — Everest Medicines (HKEX…
SHANGHAI, Dec. 20, 2023 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”)’s licensing partner Calliditas Therapeutics AB (Nasdaq:…
— Everest plans to contribute to the ongoing global Phase 2b PALIZADE trial of zetomipzomib in active lupus nephritis – …
–Clinically meaningful and statistically significant results demonstrated for primary endpoint and key secondary endpoints for the 12-week induction period– –Etrasimod…
SHANGHAI, Oct. 27, 2023 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest,” or the “Company”), a biopharmaceutical company focused on the development,…
SHANGHAI, Oct. 4, 2023 /PRNewswire/ — Everest Medicines’ (HKEX 1952.HK, “Everest”, or the “Company”) partner Calliditas Therapeutics AB (Nasdaq: CALT,…